Please login to the form below

Not currently logged in
Email:
Password:

patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

Alnylam gets EU nod for Onpattro amid pricing backlash

The  EMA has cleared Onpattro (patisiran) – the first RNA interference drug approved in the EU – for adult hATTR amyloidosis patients with stage 1 or 2 nerve damage (polyneuropathy), one of the ... intravenous injection of patisiran every three

Latest news

  • ICER says Alnylam’s Onpattro should cost 90%-95% less ICER says Alnylam’s Onpattro should cost 90%-95% less

    In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’antisense candidate Tegsedi (inotersen) which is due for an FDA

  • Alnylam claims first RNAi approval from FDA for patisiran Alnylam claims first RNAi approval from FDA for patisiran

    Alnylam claims first RNAi approval from FDA for patisiran. After years of ups and downs, triumph for gene-silencing tech. ... John Maraganore has led Alnylam since 2002. Alnylam’s chief executive – John Maraganore – estimates that there are around 3

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    The EMA’s main advisory committee backed the approval of 16 drugs at its meeting ahead of the weekend, including Alnylam’s patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis. ... The Committee for Medicinal Products for Human Use

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    The EMA’s main advisory committee backed the approval of 16 drugs at its meeting ahead of the weekend, including Alnylam’s patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis. ... The Committee for Medicinal Products for Human Use

  • The year of the blockbuster The year of the blockbuster

    Patisiran from Alnylam and Sanofi: Patisiran is an intravenously administered RNAi therapeutic targeting the transthyretin gene for the treatment of patients with debilitating hereditary transthyretin-mediated amyloidosis. ... The FDA granted patisiran

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics